Portfolio Lab

Neurocrine Biosciences Inc

  • Stock
  • Ticker NBIX
  • ISIN US64125C1099
  • Nasdaq

Health care · Biotechnology · USA

$150.57 −3.84%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Neurocrine Biosciences Inc since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

NBIXGlobal equities (VT)

$10,000 grew to $29,587. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −46.4% in 01/2022, measured from the peak in 07/2020. It took 42 months to get back to the old peak.

1-year return
+8.3%
5-year return p.a.
+11.8%
10-year return p.a.
+11.5%
Volatility p.a.
34.1%
Largest decline
−46.4%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue6285736887958068159591,123
Gross profit618563676781788801––
Operating income14224146239211193152331
EBITDA14830152246217201160340
Net income1037.9108210154198144207
Earnings per share1.000.081.062.041.481.911.391.96
Balance sheet
Total assets3,7193,6883,8904,2664,6324,9065,3595,627
Liabilities1,1291,1521,1961,2621,3781,4991,6661,749
Equity2,5902,5362,6943,0043,2533,4073,6943,879
Cash233194264340713267332642
Cash flow
Operating cash flow24365102228388146136395
Capital expenditure-7.3-11-13-132.4-9.1-7.8-12
Free cash flow2355490214391137129384

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2017 at +100.5%, weakest 2021 at −11.1%. 6 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
2 Nov 2026$1.96
31 Jul 2026$1.39
5 May 2026$1.91
11 Feb 2026$1.48
28 Oct 2025$2.04
30 Jul 2025$1.06
5 May 2025$0.08
10 Feb 2025$1.00
30 Oct 2024$1.24
1 Aug 2024$0.63
1 May 2024$0.42
9 Feb 2024$1.46

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€14bn
Market cap in trading currency
$15.2bn
Enterprise value
$14.5bn
P/E
22.3
P/S
4.12
P/B
3.93
EV/Sales
3.92
EV/EBITDA
15.8
Earnings yield
4.5%
FCF yield
6.8%

Results (last four quarters)

Revenue
$3.70bn
Gross profit
–
EBITDA
$918m
Net income
$703m
Earnings per share
$6.74
Revenue per share
$36.57
Revenue growth
+41.2%
Earnings growth
−1.4%

Profitability

Gross margin
–
Operating margin
24.0%
Net margin
19.0%
Return on equity
20.4%
Return on assets
12.5%

Balance sheet and cash flow

Cash
$738m
Cash per share
$7.29
Financial debt
–
Debt/equity %
–
Current ratio
2.04
Book value per share
$38.32
Operating cash flow
$1.07bn
Free cash flow
$1.04bn

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
101m
Volume
1.53m
Avg. volume 3 months
1.31m
Relative volume
1.2

Price and technicals

Price
$150.57
1 day
−3.8%
52-week high
$185.50
52-week low
$123.10
Distance to 52-week high
−18.8%
Distance to 52-week low
+22.3%
Distance to 50-day line
+1.0%
Distance to 200-day line
+0.8%
RSI (14)
43
Volatility 1M
56.0%

Performance

1 week
−10.1%
1 month
+5.1%
3 months
−1.6%
6 months
−3.9%
YTD
+6.2%
1 year
+9.1%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has NBIX performed since 11/2016?

$10,000 grew to $29,587 by 20 Nov 2026, which is +11.5% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is NBIX?

Volatility was 34.1% per year, measured on monthly returns. The largest decline from a peak was −46.4%, with the low in 01/2022.

How does NBIX compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, NBIX returned +11.5% at 34.1%. The correlation of monthly returns was 0.22; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Neurocrine Biosciences Inc (NBIX): Return and risk